Skip to main content
ACG 2023 Annual Meeting Posters Main banner
Back
Rate ePoster

Tuesday Poster Session

Category: IBD

P3605 - Communicating Needs and Features of IBD Experiences (CONFIDE) Survey: Prevalence and Experiences of Bowel Urgency–Comparison Between Male and Female Patients With Moderate-to-Severe Ulcerative Colitis

Tuesday, October 24, 2023
10:30 AM – 4:00 PM PT
Location: Exhibit Hall
Has Audio
Simon Travis, 1, Theresa Hunter Gibble, PhD, MPH2, Tommaso Panni, PhD3, Marla C. Dubinsky, MD4, David T. Rubin, MD, FACG5, Remo Panaccione, MD6, Toshifumi Hibi, MD, PhD7, Cem Kayhan, MD2, Alison Potts Bleakman, PhD2, Eoin Flynn, PhD2, Christian Atkinson, BSc, MRes8, Stefan Schreiber, MD9
1University of Oxford, Oxford, England, United Kingdom; 2Eli Lilly and Company, Indianapolis, IN; 3Eli Lilly and Company, Bad Homburg, Hessen, Germany; 4Mount Sinai Kravis Children’s Hospital, New York, NY; 5University of Chicago Medicine, Inflammatory Bowel Disease Center, Chicago, IL; 6University of Calgary, Calgary, AB, Canada; 7Kitasato University, Minato City, Tokyo, Japan; 8Adelphi Real World, Bollington, England, United Kingdom; 9University Hospital Schleswig-Holstein, Kiel, Schleswig-Holstein, Germany

Introduction: Here, we used data from the Communicating Needs and Features of IBD Experiences (CONFIDE) survey to compare the prevalence and experiences of bowel urgency (BU) between male and female patients in the US and Europe (EU).

Methods: An online, quantitative, cross-sectional survey was conducted among patients with moderate-to-severe UC in the US and EU5 (France, Germany, Italy, Spain, and UK). Data included patient perspectives on experience, impact, and burden of UC-related symptoms. The distribution of continuous and categorical data was compared between male and female patients using t-test and chi-square test, respectively. A p-value of < 0.05 was deemed significant, and no multiplicity adjustment was considered.

Results: 200 patients (male=123, female=77) completed the survey in the US and 556 (male=319, female=236, one patient “preferred not to say”) in the EU5. A higher proportion of males were receiving advanced therapy (65% vs. 35%). The top three symptoms experienced by male and female patients in the past month were diarrhoea (51% and 57%), BU (33% and 37%), and increased stool frequency (35% and 28%). Among the patients who had ever experienced BU, 76% male and 71% female patients reported experiencing BU at least once a week in the past 3 months. Also, 39% male and 40% female patients reported wearing a diaper/pad/other protection at least once a week in the past 3 months due to fear/anticipation of BU-related accidents. The mean Urgency Numeric Rating Scale scores (0=no urgency, 10=worst possible urgency) over the last 3 days were high among both male (7.8) and female (8.0) patients. Approximately 50% of both male and female patients reported that they needed to visit the bathroom within 5-15 min due to BU, and 2% male and 4% female patients reported not being able to make it to the bathroom in time.

Both male and female patients ranked BU and BU-related accidents among the top five most impactful symptoms and reported that BU considerably impacted their daily activities. Most patients with an experience of BU reported that it negatively affected their work or school (male=80%, female=74%).

Discussion: Bowel urgency was among the top three symptoms most frequently reported by both male and female patients with moderate-to-severe UC. The experiences and impacts of bowel urgency were largely similar between sexes and considerably affected work and daily activities of patients, irrespective of their sex.


Disclosures:
Simon Travis: AbbVie, BUHLMANN Diagnostics, ECCO, Eli Lilly and Company, Ferring Pharmaceuticals – Grant/Research Support. International Organization for the Study of Inflammatory Bowel Disease, Janssen, Merck Sharp & Dohme, Normal Collision Foundation – Grant/Research Support. Pfizer, Procter & Gamble, Schering-Plough, Takeda, UCB Pharma, Vifor Pharma, and Warner Chilcott – Grant/Research Support.
Theresa Hunter Gibble: Eli Lilly and Company – Employee, stockholder.
Tommaso Panni: Eli Lilly and Company – Employee, Stock Options.
Marla Dubinsky: AbbVie – Consultant, Grant/Research Support. Arena Pharmaceuticals – Consultant. Astra Zeneca – Consultant. Celgene – Consultant. Genentech Inc. – Consultant. Gilead Sciences – Consultant. Janssen – Consultant, Grant/Research Support. Merck – Consultant. Pfizer – Consultant, Grant/Research Support. Prometheus Biosciences – Consultant, Grant/Research Support. Prometheus Labs – Consultant, Grant/Research Support. Takeda – Consultant, Licensing fees. Thabor – Consultant. Trellus Health – Stock-publicly held company(excluding mutual/index funds). UCB Pharma – Consultant.
David Rubin: AbbVie, Alimentic Inc., Altrubio, Arena Pharmaceuticals, Aslan Pharmaceuticals, Athos Therapeutics – Consultant. Altrubio – Stock Options. American College of Gastroenterology – Advisory Committee/Board Member. Bellatrix Pharmaceuticals, Boehringer Ingelheim, Ltd., Bristol-Myers Squibb, Celgene Corp/Syneos – Consultant. ClostraBio, Connect BioPharma, EcoR1, GalenPharma/Atlantica, Genentech/Roche, Gilead Sciences, Ironwood Pharmaceuticals – Consultant. Cornerstones Health, Inc. – Cofounder and CFO. Iterative Scopes, Janssen Pharmaceuticals, Lilly USA, LLC, Materia Prima, Pfizer, Prmometheus Biosciences, Takeda, and Techlab, Inc – Consultant. Takeda – Grant/Research Support.
Remo Panaccione: Abbivax – Consultant. Abbott – Consultant. AbbVie – Consultant. Alimentiv – Consultant. Amgen – Consultant. Arena – Consultant. AstraZeneca – Consultant. Biogen – Consultant. Boehringer Ingelheim – Consultant. Bristol Myers Squibb – Consultant. Celgene – Consultant. Celltrion – Consultant. Cosmos Technology – Consultant. Eisai – Consultant. Elan – Consultant. Eli Lilly – Consultant. Ferring – Consultant. Fresenius Kabi – Consultant. Galapagos – Consultant. Genentech – Consultant. Gilead Sciences – Consultant. GlaxoSmithKline – Consultant. JAMP Bio – Consultant. Janssen – Consultant. Merck – Consultant. Mylan – Consultant. Novartis – Consultant. Oppilan Pharma – Consultant. Organon – Consultant. Pandion Pharma – Consultant. Pendopharm – Consultant. Pfizer Inc – Consultant. Progenity – Consultant. Prometheus – Consultant. Protagonist Therapeutics – Consultant. Roche – Consultant. Sandoz – Consultant. Satisfai Health – Consultant. Shire – Consultant. Sublimity Therapeutics – Consultant. Takeda Pharmaceuticals – Consultant. Theravance Biopharma – Consultant. Trellus – Consultant. UCB – Consultant. Ventyx – Consultant. Viatris – Consultant.
Toshifumi Hibi: AbbVie GK – Consultant, Grant/Research Support, Speakers Bureau. Activaid – Grant/Research Support. Alfresa Pharma – Grant/Research Support. Apo Puls Station – Advisory Committee/Board Member, Consultant. Bristol Myers Squibb – Advisory Committee/Board Member, Consultant, Grant/Research Support. Celltrion – Advisory Committee/Board Member, Consultant. EA Pharma – Advisory Committee/Board Member, Consultant, Study group sponorship. Eli Lilly and Company – Advisory Committee/Board Member, Consultant. Ferring – Grant/Research Support, Speakers Bureau. Gilead Sciences – Advisory Committee/Board Member, Consultant, Grant/Research Support, Speakers Bureau. Janssen – Advisory Committee/Board Member, Consultant, Grant/Research Support, Speakers Bureau. JIMRO – Study group sponorship, Speakers Bureau. JMDC Inc – Grant/Research Support. Kyorin – Advisory Committee/Board Member, Consultant, Study group sponsorship. Mitsubishi-TanabePharma – Advisory Committee/Board Member, Consultant, Scholarship contributions, Speakers Bureau. Mochida Pharmaceutical – Grant/Research Support, Study group sponorship, Speakers Bureau. Nichi-Iko Pharmaceutical – Advisory Committee/Board Member, Consultant. Nippon Kayaku Co – Grant/Research Support, Scholarship contributions. Otsuka Holdings – Study group sponsorship. Pfizer – Advisory Committee/Board Member, Consultant, Speakers Bureau. Pfizer Japan Inc – Grant/Research Support. Takeda – Advisory Committee/Board Member, Consultant, Grant/Research Support, Speakers Bureau. Zeria Pharmaceutical – Advisory Committee/Board Member, Consultant, Scholarship contributions and study group sponsorship.
Cem Kayhan: Eli Lilly and Company – Employee, Stock Options.
Alison Potts Bleakman: Eli Lilly and Company – Employee, Stock Options.
Eoin Flynn: Eli Lilly and Company – Employee, Stock Options.
Christian Atkinson: Adelphi Real World – Employee.
Stefan Schreiber: AbbVie – Personal fees. Amgen – Personal fees. Arena Pharmaceuticals – Personal fees. Biogen – Personal fees. Bristol Myers Squibb – Personal fees. Celgene – Personal fees. Celltrion Healthcare – Personal fees. Dr. Falk Pharma – Personal fees. Eli Lilly – personal fees. Ferring Pharmaceuticals – personal fees. Fresenius Kabi – Personal fees. Galapagos – Personal fees. Gilead – Personal fees. Hikma Pharmaceuticals – Personal fees. I-Mab – Personal fees. Janssen Pharmaceuticals – Personal fees. Morphic – Personal fees. MSD – Personal fees. Mylan – Personal fees. Pfizer – Personal fees. Protagonist – Personal fees. ProventionBio – Personal fees. Sandoz/Hexal – personal fees. Takeda – Personal fees. Theravance Biopharma – Personal fees. UCB – personal fees.


Simon Travis, 1, Theresa Hunter Gibble, PhD, MPH2, Tommaso Panni, PhD3, Marla C. Dubinsky, MD4, David T. Rubin, MD, FACG5, Remo Panaccione, MD6, Toshifumi Hibi, MD, PhD7, Cem Kayhan, MD2, Alison Potts Bleakman, PhD2, Eoin Flynn, PhD2, Christian Atkinson, BSc, MRes8, Stefan Schreiber, MD9. P3605 - Communicating Needs and Features of IBD Experiences (CONFIDE) Survey: Prevalence and Experiences of Bowel Urgency–Comparison Between Male and Female Patients With Moderate-to-Severe Ulcerative Colitis, ACG 2023 Annual Scientific Meeting Abstracts. Vancouver, BC, Canada: American College of Gastroenterology.